Sunovion Pharmaceuticals said today that it will soon begin enrollment for a Phase IV study of its anti-epileptic drug Aptiom with Empatica‘s Embrace watch. The Marlborough, Mass.-based company touted its study as the 1st to incorporate a wearable seizure device with an anti-epileptic drug into the design of a clinical trial for partial-onset seizures.
The Embrace watch is an investigational device that will be used in the study to detect and record partial-onset seizures as they are identified by patients or caregivers. Aptiom (eslicarbazepine acetate) is approved in the U.S. as a stand-alone or adjunctive therapy for partial-onset seizures.
Get the full story at our sister site, Drug Delivery Business News
The post Sunovion launches clinical trial for anti-epileptic drug with wearable tech appeared first on MassDevice.
from MassDevice http://ift.tt/2gHMGQQ
Cap comentari:
Publica un comentari a l'entrada